Instillido

Lidocaine Hydrochloride, the active ingredient in Instillido, is a local anesthetic presented as a solution for urethral use. It provides local anesthesia for urethral procedures in adult patients.

GNH USA supplies Instillido as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Instillido (lidocaine hydrochloride) is used to provide local anesthesia in the urethral tract.

- Urethral catheterization: reduces discomfort by numbing the urethral mucosa. - Urethral endoscopy: enables pain‑free visualization of the urethral lumen. - Urethral dilation: facilitates smooth passage of dilators during therapeutic procedures.

Common Side Effects: - Burning sensation at the application site. - Mild local irritation or redness. - Transient numbness extending slightly beyond the target area. - Slight swelling of the urethral mucosa. - Temporary taste alteration if solution contacts oral cavity.

Serious or Rare Side Effects: - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Systemic toxicity presenting as central nervous system symptoms (e.g., dizziness, seizures). - Cardiac arrhythmias or conduction disturbances. - Severe hypotension. - Respiratory depression in extreme overdose.

Instillido should be used with attention to patient history and administration technique.

- Assess allergy: confirm no known hypersensitivity to lidocaine or other amide‑type anesthetics. - Limit volume: apply the minimum amount required to achieve adequate anesthesia. - Monitor systemic exposure: observe patients with hepatic impairment for signs of toxicity. - Avoid concurrent use with other local anesthetics: reduce risk of additive systemic effects. - Store at room temperature: keep in the original container, protect from moisture and light.

Lidocaine may interact with several drug classes; monitoring is advised.

Major Interactions (Avoid): - Class I antiarrhythmic agents (e.g., quinidine, procainamide): can increase plasma lidocaine levels. - Strong CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic exposure. - Other local anesthetics: risk of additive toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask early signs of lidocaine toxicity. - Diuretics: can alter plasma concentration and renal clearance. - Calcium channel blockers: may enhance cardiac effects of lidocaine.